<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>P53 | Ammara Talib</title>
    <link>/tag/p53/</link>
      <atom:link href="/tag/p53/index.xml" rel="self" type="application/rss+xml" />
    <description>P53</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Sun, 24 Jan 2021 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png</url>
      <title>P53</title>
      <link>/tag/p53/</link>
    </image>
    
    <item>
      <title>Human Papillomavirus &amp; Cancer</title>
      <link>/premed-research/cancer_genetics/</link>
      <pubDate>Sun, 24 Jan 2021 00:00:00 +0000</pubDate>
      <guid>/premed-research/cancer_genetics/</guid>
      <description>&lt;p&gt;Final project for Cancer Genetics 662&lt;/p&gt;
&lt;p&gt;HPV-11 and HPV-6 are low-risk Human Papillomavirus (HPV) and cause benign anogenital warts that usually do not become cancerous. They have been shown to bind to pRB.
HPV-16 and HPV-18 are high-risk HPVs. They cause lesions that often result in cervical carcinomas and have been shown to bind to pRB. HPV-16 E6 can bind to p53 but HPV-16 E7 cannot bind to p53. Only E6 proteins of HPV-16 and HPV-18 were binding to human p53 protein. E6 of HPV-16 twice as likely to bind as E6 of HPV-18.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;picture1&#34; srcset=&#34;
               /premed-research/cancer_genetics/picture1_hua2ab1979c02265c25abb1d93afe27951_791377_0054b03b8e7aaef5c547624b31902c37.webp 400w,
               /premed-research/cancer_genetics/picture1_hua2ab1979c02265c25abb1d93afe27951_791377_3b55cc575bb68a6f2b978c60d38ea83c.webp 760w,
               /premed-research/cancer_genetics/picture1_hua2ab1979c02265c25abb1d93afe27951_791377_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;/premed-research/cancer_genetics/picture1_hua2ab1979c02265c25abb1d93afe27951_791377_0054b03b8e7aaef5c547624b31902c37.webp&#34;
               width=&#34;760&#34;
               height=&#34;679&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;In cells infected with HPV-16 and HPV-18 , there is no detectable amount of p53 protein. E6 protein may degrade wild-type p53, destroying its functionality as a tumor suppressor.&lt;/p&gt;
&lt;p&gt;The E6 Oncoprotein Encoded by Human Papillomavirus Type 16 and 18 Promotes the Degradation of p53. Presence of HPV-18 E6 leads to in vitro degradation of p53. Once p53 molecules were targeted, degradation occurred rapidly and completely.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;picture2&#34; srcset=&#34;
               /premed-research/cancer_genetics/picture2_hudfa6fad5b7118e97d5241b4495a72bde_361546_f8c49e883d6e90779369bef6e6f2294e.webp 400w,
               /premed-research/cancer_genetics/picture2_hudfa6fad5b7118e97d5241b4495a72bde_361546_25188b02c7fc1a16164076c1bcbda91a.webp 760w,
               /premed-research/cancer_genetics/picture2_hudfa6fad5b7118e97d5241b4495a72bde_361546_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;/premed-research/cancer_genetics/picture2_hudfa6fad5b7118e97d5241b4495a72bde_361546_f8c49e883d6e90779369bef6e6f2294e.webp&#34;
               width=&#34;760&#34;
               height=&#34;513&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;•	Wild-type p53 gene have tumor suppressor properties while the mutated p53 augments transformation.&lt;/p&gt;
&lt;p&gt;•	The consequence of this interaction between p53 and high-risk HPV oncoprotein would be equivalent to binding and inactivating an intracellular negative growth regulator, which can lead to unrestricted cellular proliferation.&lt;/p&gt;
&lt;p&gt;•	The mutated p53 gene has been found to be in a high percentage of human colon carcinomas and in human lung cancers.&lt;/p&gt;
&lt;p&gt;•	The elimination of wild-type p53 would be predicted to provide a growth advantage to those cells expressing E6.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;picture3&#34; srcset=&#34;
               /premed-research/cancer_genetics/picture3_hu1dd55f348f56405d9c99684b56537285_342150_732e8264c2037e6b9b76c2275565432d.webp 400w,
               /premed-research/cancer_genetics/picture3_hu1dd55f348f56405d9c99684b56537285_342150_698dde568f91170ef0b34f669bcd8423.webp 760w,
               /premed-research/cancer_genetics/picture3_hu1dd55f348f56405d9c99684b56537285_342150_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;/premed-research/cancer_genetics/picture3_hu1dd55f348f56405d9c99684b56537285_342150_732e8264c2037e6b9b76c2275565432d.webp&#34;
               width=&#34;760&#34;
               height=&#34;512&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;Figures source:&lt;/p&gt;
&lt;p&gt;Werness, B., et al. “Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53.” Science, vol. 248, no. 4951, 1990, pp. 76–79., doi:10.1126/science.2157286.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
